The Erpenbeck high frequency instability theorem for ZND detonations

The rigorous study of spectral stability for strong detonations was begun by J.J. Erpenbeck in [Er1]. Working with the Zeldovitch-von Neumann-D\"oring (ZND) model, which assumes a finite reaction rate but ignores effects like viscosity corresponding to second order derivatives, he used a normal mode analysis to define a stability function V(\tau,\eps) whose zeros in $\Re \tau>0$ correspond to multidimensional perturbations of a steady detonation profile that grow exponentially in time. Later in a remarkable paper [Er3] he provided strong evidence, by a combination of formal and rigorous arguments, that for certain classes of steady ZND profiles, unstable zeros of $V$ exist for perturbations of sufficiently large transverse wavenumber \eps, even when the von Neumann shock, regarded as a gas dynamical shock, is uniformly stable in the sense defined (nearly twenty years later) by Majda. In spite of a great deal of later numerical work devoted to computing the zeros of V(\tau,\eps), the paper \cite{Er3} remains the only work we know of that presents a detailed and convincing theoretical argument for detecting them. The analysis in [Er3] points the way toward, but does not constitute, a mathematical proof that such unstable zeros exist. In this paper we identify the mathematical issues left unresolved in [Er3] and provide proofs, together with certain simplifications and extensions, of the main conclusions about stability and instability of detonations contained in that paper. The main mathematical problem, and our principal focus here, is to determine the precise asymptotic behavior as \eps\to \infty of solutions to a linear system of ODEs in $x$, depending on \eps and a complex frequency $\tau$ as parameters, with turning points $x_*$ on the half-line $[0,\infty)$

European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease

The present guidelines on the management of limited disease small cell lung cancer (SCLC) were formulated by the ELCWP in April 2007. They are designed to answer the following seven questions: 1) What is the definition of limited disease? 2) Should chest radiotherapy be provided and what are the benefits? 3) What is the optimal timing and mode of administration of chest irradiation? 4) Which are the optimal radiotherapy parameters: dose, fractionation, target volume? 5) What is the optimal chemotherapy regimen for limited disease SCLC? 6) Should prophylactic cranial irradiation be provided, when and for which patients? 7) What is the additional role of thoracic surgery in early SCLC

An attempt to evaluate lung aggression in monkey silicosis : hydrolases, peroxidase and antiproteases activities in serial bronchoalveolar lavages

International audienc

Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study

peer reviewedNo treatment is recommended for patients with malignant mesothelioma (MM) failing after first-line cisplatin-based chemotherapy. In vitro data suggested that valproic acid, a histone deacetylase inhibitor (HDACi), had a proapoptotic effect and synergised with doxorubicin to induce apoptosis in MM cells. Our primary end-point was to determine response rate of combined valproic acid and doxorubicin in patients with unresectable MM failing after platinum based chemotherapy. Treatment consisted of doxorubicin (60 mg?m-2) plus valproic acid. An interim analysis for response rate was planned after the first 16 registered patients. All the cases were centrally reviewed. From July 2006 to March 2009, 45 eligible patients with pleural MM were registered. The majority of the patients were male (73%), had a performance status (PS) o80 (76%) and an epithelioid subtype (80%). There were seven partial responses (response rate 16%; 95% CI 3– 25%), all in patients with PS 80–100. The best disease control rate was 36% (95% CI 22–51%). Two toxic deaths were observed (febrile neutropenia and cerebral thrombotic event), both in patients with poor PS (60–70). Valproic acid, an HDACi, plus doxorubicin appeared an effective chemotherapy regimen in good PS (80–100) patients with refractory or recurrent MM, for which no standard therapy was available

Constraining velocity-dependent Lorentz and CPTCPT violations using lunar laser ranging

International audienceThe possibility for Lorentz and CPT breaking, which is motivated by unification theories, can be systematically tested within the Standard Model extension (SME) framework. In the pure gravity sector, the mass dimension 5 operators produce new Lorentz- and CPT-breaking terms in the two-body equations of motion that depend on the relative velocity of the bodies, and, hence, they can be constrained with gravity experiments. In this paper, we report new constraints on 15 independent SME coefficients for Lorentz and CPT violations with mass dimension 5 using lunar laser ranging. We perform a global analysis of lunar ranging data within the SME framework using more than 26 000 normal points between 1969 and 2018. We also perform a jackknife analysis in order to provide realistic estimates of the systematic uncertainties. No deviation from Lorentz and CPT symmetries is reported. In addition, when fitting simultaneously for the 15 canonical SME coefficients for Lorentz and CPT violations, we improve up to 3 orders of magnitude previous postfit constraints from radio pulsars

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe